A Study to Evaluate Lanraplenib (LANRA) in Combination With Gilteritinib in Participants With FLT3-mutated Relapsed or Refractory Acute Myeloid Leukemia (AML)
Summary
- Eligibility
- for people ages 18 years and up (full criteria)
- Location
- at Los Angeles, California and other locations
- Dates
- study startestimated completion
- Principal Investigator
- by Gary Schiller
Description
Summary
Official Title
Keywords
Eligibility
Locations
Lead Scientist at UCLA
- Gary Schiller
Professor-in-Residence, Medicine. Authored (or co-authored) 146 research publications
Details
- Status
- accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Kronos Bio
- Links
- Sign up for this study
- ID
- NCT05028751
- Phase
- Phase 1/2 research study
- Study Type
- Interventional
- Participants
- Expecting 100 study participants
- Last Updated